# US 2026/0035669 A1 · Methods and compositions for producing granulosa-like cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0035669 A1
- Document ID: US20260035669A1
- Status: Published application
- Kind: A1
- Application number: 19/361,681
- Filed: 2025-10-17
- Published: 2026-02-05
- Earliest claimed: 2022-04-01
- Assignees: President and Fellows of Harvard College
- Applicants: President and Fellows of Harvard College
- Inventors: Merrick Pierson Smela; Christian Kramme; Pranam Chatterjee; George M. Church
- Web page: https://patentgrep.com/patent/US20260035669A1

## CPC

- C12N 5/0682: {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N5/0609)}
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- C12N 2501/60: Transcription factors
- C12N 2502/04: germ cells
- C12N 2502/243: Cells of the female genital tract, non-germinal ovarian cells
- C12N 2506/45: from artificially induced pluripotent stem cells
- C12N 2510/00: Genetically modified cells
- C12N 2533/52: Fibronectin; Laminin
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Provided herein are methods and compositions for differentiating induced pluripotent stem cells into granulosa-like cells by overexpressing transcription factors such as NR5A1 and a RUNX family protein (e.g., RUNX1 and/or RUNX2).

## Claims

### Claim at position 1

-58. (canceled)

### Claim 59

A human induced pluripotent stem cell (hiPSC) comprising:
(i) an exogenous polynucleotide comprising an open reading frame encoding NR5A1 protein; and
(ii) an exogenous polynucleotide comprising an open reading frame encoding RUNX1 protein.

### Claim 60 (depends on 59)

The hiPSC of claim 59, wherein the hiPSC further comprises an exogenous polynucleotide comprising an open reading frame encoding GATA4 protein.

### Claim 61 (depends on 59)

The hiPSC of claim 59, wherein the hiPSC further comprises an exogenous polynucleotide comprising an open reading frame encoding TCF21 protein.

### Claim 62 (depends on 60)

The hiPSC of claim 60, wherein the hiPSC further comprises an exogenous polynucleotide comprising an open reading frame encoding TCF21 protein.

### Claim 63 (depends on 59)

The hiPSC of claim 59, wherein each of the open reading frames is operably linked to a heterologous promoter.

### Claim 64 (depends on 63)

The hiPSC of claim 63, wherein each heterologous promoter is independently selected from an alcohol-regulated promoter, a steroid-regulated promoter, a metal-regulated promoter, a pathogenesis-regulated promoter, a temperature-inducible promoter, and a light-responsive promoter.

### Claim 65 (depends on 64)

The hiPSC of claim 64, wherein:
(i) the pathogenesis-regulated promoter is a promoter that is inducible by salicylic acid, ethylene, or benzothiadiazole; and/or
(ii) the temperature-inducible promoter is a heat shock promoter.

### Claim 66 (depends on 63)

The hiPSC of claim 63, wherein each heterologous promoter is independently a tetracycline-inducible promoter or a doxycycline-inducible promoter.

### Claim 67 (depends on 59)

The hiPSC of claim 59, wherein the NR5A1 protein has the amino acid sequence of SEQ ID NO: 1 and the RUNX1 protein has the amino acid sequence of SEQ ID NO: 2.

### Claim 68 (depends on 60)

The hiPSC of claim 60, wherein the GATA4 protein has the amino acid sequence of SEQ ID NO: 5.

### Claim 69 (depends on 61)

The hiPSC of claim 61, wherein the TCF21 protein has the amino acid sequence of SEQ ID NO: 4.

### Claim 70 (depends on 59)

The hiPSC of claim 59, wherein each of the polynucleotides is present within a single nucleic acid molecule.

### Claim 71 (depends on 59)

The hiPSC of claim 59, wherein each of the polynucleotides is present within separate nucleic acid molecules.

### Claim 72

A population of hiPSCs, wherein a plurality of the hiPSCs in the population comprises:
(i) an exogenous polynucleotide comprising an open reading frame encoding NR5A1 protein; and
(ii) an exogenous polynucleotide comprising an open reading frame encoding RUNX1 protein.

### Claim 73 (depends on 72)

The population of hiPSCs of claim 72, wherein the plurality of the hiPSCs in the population further comprises an exogenous polynucleotide comprising an open reading frame encoding GATA4 protein.

### Claim 74 (depends on 72)

The population of hiPSCs of claim 72, wherein the plurality of the hiPSCs in the population further comprises an exogenous polynucleotide comprising an open reading frame encoding TCF21 protein.

### Claim 75 (depends on 73)

The population of hiPSCs of claim 73, wherein the plurality of the hiPSCs in the population further comprises an exogenous polynucleotide comprising an open reading frame encoding TCF21 protein.

### Claim 76 (depends on 72)

The population of hiPSCs of claim 72, wherein each of the open reading frames is operably linked to a heterologous promoter.

### Claim 77 (depends on 76)

The population of hiPSCs of claim 76, wherein each heterologous promoter is independently selected from an alcohol-regulated promoter, a steroid-regulated promoter, a metal-regulated promoter, a pathogenesis-regulated promoter, a temperature-inducible promoter, and a light-responsive promoter.

### Claim 78 (depends on 77)

The population of hiPSCs of claim 77, wherein:
(i) the pathogenesis-regulated promoter is a promoter that is inducible by salicylic acid, ethylene, or benzothiadiazole; and/or
(ii) the temperature-inducible promoter is a heat shock promoter.

### Claim 79 (depends on 76)

The population of hiPSCs of claim 76, wherein each heterologous promoter is independently a tetracycline-inducible promoter or a doxycycline-inducible promoter.

### Claim 80 (depends on 72)

The population of hiPSCs of claim 72, wherein the NR5A1 protein has the amino acid sequence of SEQ ID NO: 1 and the RUNX1 protein has the amino acid sequence of SEQ ID NO: 2.

### Claim 81 (depends on 80)

The population of hiPSCs of claim 80, wherein the plurality of the hiPSCs in the population further comprise an exogenous polynucleotide comprising an open reading frame encoding GATA4 protein, and wherein the GATA4 protein has the amino acid sequence of SEQ ID NO: 5.

### Claim 82 (depends on 81)

The population of hiPSCs of claim 81, wherein the plurality of the hiPSCs in the population further comprise an exogenous polynucleotide comprising an open reading frame encoding TCF21 protein, and wherein the TCF21 protein has the amino acid sequence of SEQ ID NO: 4.

### Claim 83 (depends on 72)

The population of hiPSCs of claim 72, wherein the plurality of the hiPSCs comprises from 1×102 to 1×107 hiPSCs.

### Claim 84

A method of producing a population of cells that express one or more of AMHR2, CD82, and FOXL2, and that do not express detectable levels of EPCAM, the method comprising:
(i) transfecting one or more hiPSCs to express:
(a) a polynucleotide comprising an open reading frame encoding NR5A1 protein having the amino acid sequence of SEQ ID NO: 1, and
(b) polynucleotide comprising an open reading frame encoding RUNX1 protein having the amino acid sequence of SEQ ID NO: 2; and
(ii) culturing the one or more cells resulting from (i) in culture media, thereby producing a population of cells that express one or more of AMHR2, CD82, and FOXL2, and that do not express detectable levels of EPCAM.

### Claim 85 (depends on 84)

The method of claim 84, wherein the one or more hiPSCs are further transfected to express a polynucleotide comprising an open reading frame encoding GATA4 protein having the amino acid sequence of SEQ ID NO: 5, and/or wherein the one or more hiPSCs are further transfected to express a polynucleotide comprising an open reading frame encoding TCF21 protein having the amino acid sequence of SEQ ID NO: 4.

### Claim 86 (depends on 85)

The method of claim 85, wherein the culturing of (ii) is conducted in the presence of:
(i) CHIR99021, represented by the structural formula:
and
(ii) Y-27632, represented by the structural formula:

### Claim 87 (depends on 86)

The method of claim 86, wherein the culturing of (ii) is conducted for from 4 days to 7 days, optionally wherein the culturing of (ii) is conducted for 5 days.

### Claim 88 (depends on 87)

The method of claim 87, wherein the cells resulting from (ii) express one or more of the following sets of proteins:
(a) β-catenin, α-catenin, N-cadherin, nectin-1, nectin-2, and nectin-3;
(b) junctional adhesion molecule-A (JAM-A) and cingulin;
(c) desmoglein 2 (DSG2) and desmocollin 2 (Dsc2); and
(d) afadin, Zonula occludens-1 (ZO-1) and Zonula occludens-2 (ZO-2) and ZO-1-associated nucleic acid-binding protein (ZONAB).
